Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GART | P22102 | 16/20 | 0.90 |
| ▸ | FOLR1 | P15328 | 12/20 | 0.90 |
| ▸ | FOLR2 | P14207 | 11/20 | 0.90 |
| ▸ | SLC46A1 | Q96NT5 | 11/20 | 0.90 |
| ▸ | SLC19A1 | P41440 | 5/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18540804 | 0.95 | GART (1.00) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL18551644 | 0.95 | GART (1.00) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL18158248 | 0.95 | GART (1.00) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL28720520 | 0.90 | GART (0.79) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL28720517 | 0.90 | GART (0.79) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL18160916 | 0.87 | GART (0.80) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL18160918 | 0.87 | GART (1.00) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL12011079 | 0.86 | GART (0.71) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL18160919 | 0.86 | GART (1.00) | GARTFOLR1FOLR2SLC46A1SLC19A1 | |
| SCHEMBL9844824 | 0.86 | GART (0.68) | GARTFOLR1FOLR2SLC46A1SLC19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466111-B2 | Cyclopenta{G}quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia | BTG INTERNATIONAL LIMITED (GB) | 2013-06-18 | — | — | US | disclosed |
| US-8466111-B2 | Cyclopenta{G}quinazoline derivatives for the treatment of rheumatoid arthritis or acute myeloid leukaemia | BTG INTERNATIONAL LIMITED (GB) | 2013-06-18 | — | — | US | disclosed |
| EP-2293807-B1 | CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INT LTD (GB) | 2012-05-09 | — | — | EP | disclosed |
| US-20110190211-A1 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INTERNATIONAL LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| US-20110190211-A1 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INTERNATIONAL LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| WO-2009115776-A1 | CYCLOPENTA[G]QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | BTG INTERNATIONAL LIMITED (GB) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190211-A1 | CYCLOPENTAQUINAZOLINE DERIVATIVES FOR THE TREATMENT OF RHEUMATOID ARTHRITIS OR ACUTE MYELOID LEUKAEMIA | ARGLU1, MCL1, GLUL | GART 968/4885FOLR1 2188/4885FOLR2 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.